Indicator type	Size of the company	Total
Number of companies carrying out R&D in Biotechnology	Less than 250 employees	1.221
Number of companies carrying out R&D in Biotechnology	250 and more employees	156
Number of companies carrying out R&D in Biotechnology	Total	1.376
% Companies by type of biotechnology used: Genetic Code	Less than 250 employees	30,2
% Companies by type of biotechnology used: Genetic Code	250 and more employees	41,5
% Companies by type of biotechnology used: Genetic Code	Total	31,4
% Companies by type of biotechnology used: Functional Units	Less than 250 employees	42,4
% Companies by type of biotechnology used: Functional Units	250 and more employees	54,3
% Companies by type of biotechnology used: Functional Units	Total	43,7
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Less than 250 employees	21,2
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	250 and more employees	35,9
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Total	22,8
% Companies by type of biotechnology used: Bioprocesses	Less than 250 employees	46,1
% Companies by type of biotechnology used: Bioprocesses	250 and more employees	65,3
% Companies by type of biotechnology used: Bioprocesses	Total	48,3
% Companies by type of biotechnology used: Subcellular Organisms	Less than 250 employees	7
% Companies by type of biotechnology used: Subcellular Organisms	250 and more employees	14,6
% Companies by type of biotechnology used: Subcellular Organisms	Total	7,9
% Companies by type of biotechnology used: Bioinformatics	Less than 250 employees	26,5
% Companies by type of biotechnology used: Bioinformatics	250 and more employees	32,5
% Companies by type of biotechnology used: Bioinformatics	Total	27,1
% Companies by type of biotechnology used: Nanobiotechnology	Less than 250 employees	11
% Companies by type of biotechnology used: Nanobiotechnology	250 and more employees	13,4
% Companies by type of biotechnology used: Nanobiotechnology	Total	11,2
% Companies by type of biotechnology used: Other	Less than 250 employees	18,1
% Companies by type of biotechnology used: Other	250 and more employees	14
% Companies by type of biotechnology used: Other	Total	17,6
Companies in which biotechnology activities are: Main and/or exclusive	Less than 250 employees	686
Companies in which biotechnology activities are: Main and/or exclusive	250 and more employees	25
Companies in which biotechnology activities are: Main and/or exclusive	Total	711
Companies in which biotechnology activities are: A secondary business line	Less than 250 employees	214
Companies in which biotechnology activities are: A secondary business line	250 and more employees	55
Companies in which biotechnology activities are: A secondary business line	Total	270
Companies in which biotechnology activities are: A necessary tool for production	Less than 250 employees	320
Companies in which biotechnology activities are: A necessary tool for production	250 and more employees	75
Companies in which biotechnology activities are: A necessary tool for production	Total	395
% Companies by final application areas of biotechnology use: Human Health	Less than 250 employees	48,7
% Companies by final application areas of biotechnology use: Human Health	250 and more employees	42,7
% Companies by final application areas of biotechnology use: Human Health	Total	48
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Less than 250 employees	16,7
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	250 and more employees	17,9
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Total	16,9
% Companies by final application areas of biotechnology use: Food Products	Less than 250 employees	28
% Companies by final application areas of biotechnology use: Food Products	250 and more employees	40,1
% Companies by final application areas of biotechnology use: Food Products	Total	29,4
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Less than 250 employees	26,1
% Companies by final application areas of biotechnology use: Agriculture and Forestry	250 and more employees	22,6
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Total	25,7
% Companies by final application areas of biotechnology use: Environment	Less than 250 employees	17,9
% Companies by final application areas of biotechnology use: Environment	250 and more employees	18,9
% Companies by final application areas of biotechnology use: Environment	Total	18
% Companies by final application areas of biotechnology use: Industry	Less than 250 employees	12,6
% Companies by final application areas of biotechnology use: Industry	250 and more employees	16,5
% Companies by final application areas of biotechnology use: Industry	Total	13
R&D personnel in Biotechnology (PP)	Less than 250 employees	10.421
R&D personnel in Biotechnology (PP)	250 and more employees	6.836
R&D personnel in Biotechnology (PP)	Total	17.257
R&D personnel in Biotechnology (PP): Research personnel	Less than 250 employees	6.087
R&D personnel in Biotechnology (PP): Research personnel	250 and more employees	3.108
R&D personnel in Biotechnology (PP): Research personnel	Total	9.195
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Less than 250 employees	4.333
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	250 and more employees	3.728
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Total	8.061
R&D personnel in Biotechnology (PP). Women	Less than 250 employees	5.700
R&D personnel in Biotechnology (PP). Women	250 and more employees	4.280
R&D personnel in Biotechnology (PP). Women	Total	9.980
R&D personnel in Biotechnology (PP). Women: Research personnel	Less than 250 employees	3.359
R&D personnel in Biotechnology (PP). Women: Research personnel	250 and more employees	1.863
R&D personnel in Biotechnology (PP). Women: Research personnel	Total	5.222
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Less than 250 employees	2.341
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	250 and more employees	2.417
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Total	4.758
R&D personnel in Biotechnology (FTE)	Less than 250 employees	7.562,8
R&D personnel in Biotechnology (FTE)	250 and more employees	5.320,6
R&D personnel in Biotechnology (FTE)	Total	12.883,4
R&D personnel in Biotechnology (FTE): Research personnel	Less than 250 employees	4.665,3
R&D personnel in Biotechnology (FTE): Research personnel	250 and more employees	2.437,9
R&D personnel in Biotechnology (FTE): Research personnel	Total	7.103,2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Less than 250 employees	2.897,4
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	250 and more employees	2.882,8
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Total	5.780,2
R&D personnel in Biotechnology (FTE). Women	Less than 250 employees	4.222
R&D personnel in Biotechnology (FTE). Women	250 and more employees	3.378,6
R&D personnel in Biotechnology (FTE). Women	Total	7.600,6
R&D personnel in Biotechnology (FTE). Women: Research personnel	Less than 250 employees	2.605,7
R&D personnel in Biotechnology (FTE). Women: Research personnel	250 and more employees	1.451,3
R&D personnel in Biotechnology (FTE). Women: Research personnel	Total	4.057
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Less than 250 employees	1.616,3
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	250 and more employees	1.927,3
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Total	3.543,7
Expenditure on internal R&D in Biotechnology (thousands of euros)	Less than 250 employees	794.091
Expenditure on internal R&D in Biotechnology (thousands of euros)	250 and more employees	489.255
Expenditure on internal R&D in Biotechnology (thousands of euros)	Total	1.283.346
1) By type of expenditure: Current expenditure	Less than 250 employees	715.652
1) By type of expenditure: Current expenditure	250 and more employees	464.535
1) By type of expenditure: Current expenditure	Total	1.180.187
1.1) Labour expenditure of research personnel	Less than 250 employees	235.238
1.1) Labour expenditure of research personnel	250 and more employees	137.183
1.1) Labour expenditure of research personnel	Total	372.421
1.2) Labour expenditure of technical and auxiliary personnel	Less than 250 employees	113.075
1.2) Labour expenditure of technical and auxiliary personnel	250 and more employees	116.659
1.2) Labour expenditure of technical and auxiliary personnel	Total	229.734
1.3) Other current expenditure	Less than 250 employees	367.339
1.3) Other current expenditure	250 and more employees	210.693
1.3) Other current expenditure	Total	578.032
2) By type of expenditure: Capital expenditure	Less than 250 employees	78.439
2) By type of expenditure: Capital expenditure	250 and more employees	24.720
2) By type of expenditure: Capital expenditure	Total	103.159
2.1) Land and buildings	Less than 250 employees	8.547
2.1) Land and buildings	250 and more employees	2.342
2.1) Land and buildings	Total	10.889
2.2) Equipment and tools	Less than 250 employees	40.395
2.2) Equipment and tools	250 and more employees	18.809
2.2) Equipment and tools	Total	59.204
2.3) Acquisition of specific R&D software	Less than 250 employees	4.415
2.3) Acquisition of specific R&D software	250 and more employees	1.208
2.3) Acquisition of specific R&D software	Total	5.623
2.4) Other R&D-specific IP products	Less than 250 employees	25.082
2.4) Other R&D-specific IP products	250 and more employees	2.360
2.4) Other R&D-specific IP products	Total	27.442
1.1) By origin of funds: Own funds	Less than 250 employees	548.276
1.1) By origin of funds: Own funds	250 and more employees	339.251
1.1) By origin of funds: Own funds	Total	887.527
1.2) By origin of funds: Funds from the Business sector	Less than 250 employees	96.237
1.2) By origin of funds: Funds from the Business sector	250 and more employees	47.667
1.2) By origin of funds: Funds from the Business sector	Total	143.903
1.3) By origin of funds: Funds from the Public Administration sector	Less than 250 employees	98.923
1.3) By origin of funds: Funds from the Public Administration sector	250 and more employees	27.623
1.3) By origin of funds: Funds from the Public Administration sector	Total	126.546
1.4) By origin of funds: Funds from the Higher Education sector	Less than 250 employees	94
1.4) By origin of funds: Funds from the Higher Education sector	250 and more employees	0
1.4) By origin of funds: Funds from the Higher Education sector	Total	94
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Less than 250 employees	2.684
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	250 and more employees	9.939
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Total	12.623
1.6) By origin of funds: Funds from the rest of the world	Less than 250 employees	47.877
1.6) By origin of funds: Funds from the rest of the world	250 and more employees	64.776
1.6) By origin of funds: Funds from the rest of the world	Total	112.652
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Less than 250 employees	76.773
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	250 and more employees	60.659
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Total	137.432
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Less than 250 employees	38.607
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	250 and more employees	49.521
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Total	88.127
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Less than 250 employees	38.166
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	250 and more employees	11.139
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Total	49.305
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Less than 250 employees	46,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	250 and more employees	23,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Total	43,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Less than 250 employees	16,3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	250 and more employees	15,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Total	16,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Less than 250 employees	24,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	250 and more employees	16
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Total	23,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Less than 250 employees	14,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	250 and more employees	14,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Total	14,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Less than 250 employees	19
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	250 and more employees	10,5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Total	18,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Less than 250 employees	20,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	250 and more employees	12,9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Total	19,6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Less than 250 employees	18,9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	250 and more employees	21,2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Total	19,1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Less than 250 employees	51
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	250 and more employees	40,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Total	49,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Less than 250 employees	61
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	250 and more employees	46,8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Total	59,4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Less than 250 employees	23,7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	250 and more employees	11
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Total	22,3
% Companies with international revenues related to biotechnology activities	Less than 250 employees	23,6
% Companies with international revenues related to biotechnology activities	250 and more employees	22,7
% Companies with international revenues related to biotechnology activities	Total	23,6
% Companies representing international revenues related to biotechnology activities	Less than 250 employees	6,9
% Companies representing international revenues related to biotechnology activities	250 and more employees	1
% Companies representing international revenues related to biotechnology activities	Total	1,5
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Less than 250 employees	50
% International revenues related to biotechnology activities distributed in: Revenues from the EU	250 and more employees	62,8
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Total	57,6
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Less than 250 employees	50
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	250 and more employees	37,2
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Total	42,4
% International revenues related to biotechnology activities by classification: International trade in goods and services	Less than 250 employees	91,4
% International revenues related to biotechnology activities by classification: International trade in goods and services	250 and more employees	76,2
% International revenues related to biotechnology activities by classification: International trade in goods and services	Total	82,3
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Less than 250 employees	4,5
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	250 and more employees	20,6
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Total	14,1
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Less than 250 employees	1
% International revenues related to biotechnology activities by classification: Subsidies from external sources	250 and more employees	1,8
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Total	1,5
% International revenues related to biotechnology activities by classification: Other	Less than 250 employees	3,1
% International revenues related to biotechnology activities by classification: Other	250 and more employees	1,4
% International revenues related to biotechnology activities by classification: Other	Total	2,1